Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465246 | 0.91 | PI4KB (0.37) | ATRPI4KBSREBF2CYP17A1CA1 | |
| SCHEMBL26456528 | 0.76 | PI4KB (0.40) | ATRPI4KBCYP17A1CA1CA2 | |
| SCHEMBL10437433 | 0.76 | NLRP3 (0.56) | ATRLCKNLRP3NQO2 | |
| SCHEMBL23960309 | 0.75 | ATR (0.41) | ATRPI4KBCYP17A1CA1CA2 | |
| SCHEMBL23960254 | 0.74 | ATR (0.40) | ATRPI4KBCYP17A1CA1CA2 | |
| SCHEMBL3030230 | 0.73 | LCK (0.44) | ATRCYP17A1LCKNLRP3NQO2 | |
| SCHEMBL9291305 | 0.73 | MEN1 (0.44) | ATRPI4KBCA1CA2CTSL | |
| SCHEMBL22774803 | 0.72 | LCK (0.45) | ATRPI4KBCA1CA2LCK | |
| SCHEMBL23960283 | 0.72 | ATR (0.41) | ATRPI4KBCYP17A1CA1CA2 | |
| SCHEMBL23289627 | 0.72 | CNR2 (0.44) | LCKCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | NodThera Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| EP-3983407-B1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NODTHERA LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| CN-114222739-B | Sulfonylurea derivatives and their use | 诺瑟拉有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20230083495-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-3983407-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114222739-A | Sulfonylurea derivatives and use thereof | 诺瑟拉有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | PYCARD, NOD1, NLRP3 | ATR 3908/4885PI4KB 2864/4885SREBF2 3596/4885 |
| US-20230083495-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | IL1B, NOD1, IL1A | ATR 4416/4885PI4KB 1673/4885SREBF2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.